Patents Assigned to Biofrontera Pharmaceuticals GmbH
  • Patent number: 6790992
    Abstract: The present invention relates to novel scyphostatin analogues, which distinguish themselves by acting as SMase inhibitors so that they are of therapeutic use for a number of diseases such as a HIV infection, neurodegenerative diseases, inflammatory diseases, apoplexy, ischemia, myocardial infarction or in the case of atherosclerosis.
    Type: Grant
    Filed: August 22, 2002
    Date of Patent: September 14, 2004
    Assignee: Biofrontera Pharmaceuticals GmbH
    Inventor: Hans-Peter Deigner
  • Patent number: 6670121
    Abstract: The invention relates to methods for the qualitative and quantitative determination of differentially expressed mRNA molecules. Said methods are used especially to determine all possible mRNA molecules present in a cell or a tissue, and to compare them with other cells or tissues, with other conditions (stages of disease or development), or with stages of treatment for these conditions. The method provided for in the invention therefore makes it possible, for example, to establish a comprehensive map of the different mRNA molecules present in a defined mRNA population and subsequently to use the preferably digital information obtained in this way in data base analyses.
    Type: Grant
    Filed: October 24, 2000
    Date of Patent: December 30, 2003
    Assignee: Biofrontera Pharmaceuticals GmbH
    Inventors: Ralf Hoffmann, Hermann Lübbert, Stefan Zwilling